MedTrace Logo

Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

NCT02230306 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2017-10-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effectiveness of the combination of vemurafenib with cobimetinib in patients with active melanoma brain metastases.

Conditions

  • Active Melanoma Brain Metastases

Interventions

DRUG

Cobimetinib

60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;

DRUG

Vemurafenib

960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Melissa Burgess, MD

    lead OTHER

Principal Investigators

  • Melissa Burgess, MD · University of Pittsburgh

  • Richard Carvajal, MD · Memorial Sloan Kettering Cancer Center

  • Anna Pavlick, MD · NYU Clinical Cancer Center

  • Mohammed Milhem, MD · Univ of Iowa

  • Ravi Amaravadi, MD · Univ of Pennsylvania

  • Harriet Kluger, MD · Yale New Haven Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02230306 on ClinicalTrials.gov